嘉事堂表示，根据《深圳证券交易所股票上市规则》《深圳证券交易所上市公司自律监管指引第6号 ——停复牌》等有关规定，经公司向深交所申请，公司股票自2月4日上午开市起复牌。 北京商报讯(记者丁宁)2月3日晚间，嘉事堂（002462）发布公告称，2月2日，公司股东光大实业、光大 健康与中国北京同仁堂（600085）(集团)有限责任公司(以下简称"同仁堂集团")签署了《股份转让协 议》，协议约定光大实业、光大健康分别将其持有的公司4118.08万股股份、4187.64万股股份转让给同 仁堂集团。本次交易完成后，公司控股股东将变更为同仁堂集团，实际控制人将变更为北京市人民政府 国有资产监督管理委员会。 ...

2月3日，北京2026年首场土拍正式开启，三宗宅地总出让金额达57.62亿元。此次出让的地块分别位于石景山区、通州区及顺义区。其中，顺义区新国展三 期SY00-2301-0003、0004、0005地块（以下简称"新国展地块"）由中国铁工投资集团摘得。北京商报记者梳理发现，中国铁工投资集团作为中国中铁旗下全 资子公司，此前在北京多以一级开发、城市更新合作方或联合体成员身份参与城市建设，极少独立在公开市场竞得住宅用地。此次成功拿地，意味着该企业 首次进入北京商品住宅用地市场，也成为本次土拍的一大看点。 同日，北京发布2026年第一轮拟供商品住宅用地清单，共涉及5宗地，土地面积约16公顷，建筑规模约24万平方米，上述用地拟于近期供应。 中指研究院土地市场研究负责人张凯表示，本次土拍全部以底价成交，与2025年初高溢价抢拍现象形成对比。这种反差实际上延续了2025年北京土地市 场"量减价升"的整体格局。根据北京市规划和自然资源委员会发布的《北京市2026年度建设用地供应计划》，今年北京商品住宅用地安排200—240公顷，较 2025年的240—300公顷继续缩量，这已是连续第四年缩减。在供应缩量的背景下，土地出让的 ...

北京商报讯（记者 李秀梅）2月3日，香港保险业监管局（保监局）表示，宏福苑大火发生后，香港保 监局全力协调保险公司为受影响人士提供支援，并密切监察处理理赔个案的进度。数据显示，至今1032 宗（85%）个案已处理完毕，涉及金额近5.1亿港元。 香港保监局行政总监张云正表示："保监局得悉大部分理赔个案已成功在基于公平待客的原则下获得解 决，而余下个案则须作出实地勘察和损毁评估，我们会继续与香港保险业联会积极跟进。" 据悉，一般保险理赔个案共1030宗，其中863宗已处理完毕（84%），涉及金额约4.5亿港元；人寿保险 理赔个案共188宗，其中169宗（90%）已处理完毕，涉及金额约6000万港元。 ...

Core Viewpoint - The central document emphasizes the importance of protecting and incentivizing farmers in agricultural production, aiming for modernization and comprehensive rural revitalization by 2026 [1] Policy Support - The document outlines the need for enhanced support through pricing, subsidies, and insurance to ensure farmers' income security [1] - It highlights the importance of strengthening insurance mechanisms specifically for rice, wheat, corn, and soybeans [1] Insurance Efficiency - There is a focus on improving the efficiency of insurance claims processing for agricultural products [1] - The document encourages the development of insurance for local specialty agricultural products [1]

Core Insights - Tmall released the "2026 Tmall Cultural and Creative Industry Trend Report," highlighting key consumer trends in the cultural and creative sector [1] - The report indicates that female consumers under 30 years old are the primary drivers of cultural and creative consumption, accounting for nearly 70% of the market [1] - Tmall plans to heavily invest in the cultural and creative sector by launching a dedicated channel and aims to incubate 100 new cultural products with sales exceeding 1 million yuan each by 2026 [1] Consumer Behavior - Cultural and creative consumption is primarily focused on gifting, decoration, blessings, and weddings [1] - Over 80% of consumers purchase cultural products at least once every two months, with 43.4% willing to pay between 50 to 200 yuan for a single item [1] - Emotional and interest-driven consumption has become the mainstream mindset, representing 40% of consumer behavior [1] Market Trends - The top three areas where consumers are willing to spend for emotional value and interest include travel, gaming, and music festivals [1] - Tmall has established official flagship stores for 77 domestic and international museums, with plans to launch over 5,000 new cultural products by 2025 [1] - In the past year, 700 million visits were recorded on Taobao and Tmall for museum browsing, with users aged 18 to 34 making up over 80% of this demographic [1]

Core Viewpoint - *ST Lifan (300344) announced that it has completed an internal review regarding stock price fluctuations and will resume trading on February 4 [2] Group 1: Stock Performance - From January 20 to January 29, *ST Lifan experienced a significant price increase, with 5 out of 8 trading days hitting the daily limit, resulting in a total price increase of 188.06% [2] - The stock has shown abnormal trading fluctuations during this period, indicating a potential overreaction in market sentiment [2] Group 2: Company Fundamentals - The company stated that its stock price has significantly deviated from its fundamental value, suggesting risks of market overheating and irrational speculation [2] - There is a possibility that the company may face forced delisting due to major legal violations [2]

Core Viewpoint - BGI Genomics (688114) plans to acquire 100% equity of two companies, Shenzhen BGI Sanjian Qifa Technology Co., Ltd. and Hangzhou BGI Xufeng Technology Co., Ltd., for a total of 366 million yuan, integrating cutting-edge technologies in spatial omics and nanopore sequencing into its business [2][4]. Group 1: Acquisition Details - The total transaction price for the acquisition is 366 million yuan, with BGI Sanjian Qifa valued at 158 million yuan and BGI Xufeng at 208 million yuan [4]. - BGI Genomics will also inject 70 million yuan and 60 million yuan into BGI Sanjian Qifa and BGI Xufeng, respectively, to support their operations and business expansion [4]. - A loan of 70 million yuan will be provided to BGI Xufeng at an interest rate of 2.5% for three years to repay debts [4]. Group 2: Financial Performance and Projections - Both BGI Sanjian Qifa and BGI Xufeng are currently in the R&D phase and have not yet achieved profitability, with projected revenues of 607.43 million yuan and 279.96 million yuan for BGI Sanjian Qifa in 2024 and 2025, respectively [6]. - BGI Xufeng is expected to generate revenues of 440.23 million yuan and 661.38 million yuan in the same periods, with significant net losses reported [6]. - Profitability is anticipated for BGI Sanjian Qifa and BGI Xufeng by 2026 and 2028, respectively, with performance commitments set for net profits during these years [7][11]. Group 3: Strategic Implications - The acquisition will enable BGI Genomics to create a comprehensive technology chain covering short-read, long-read, and spatial omics technologies, positioning it uniquely in the global market [6][8]. - The integration of these technologies is expected to enhance BGI Genomics' competitive edge and profitability in the long term, potentially serving as a new growth engine [7][8]. - The strategic alignment of BGI Sanjian Qifa's spatial omics with BGI Genomics' existing platforms is anticipated to attract new customers and meet complex research needs [8]. Group 4: Valuation and Market Considerations - The valuation of BGI Sanjian Qifa shows a high appreciation rate of 2460.66%, while BGI Xufeng has a valuation increase of 296.55% [9][10]. - The assessment of these companies considers not only tangible assets but also intangible resources such as brand, technology, and customer relationships [10]. - The transaction is viewed as having a strong cost advantage compared to industry peers, with dynamic price-to-sales ratios around 3 times lower than comparable companies in their respective fields [10].

据了解，工银万事达欧洲旅行联名信用卡以欧洲文旅场景为特色，构建起覆盖"吃、住、行、游、购、娱"的全链条权益体系，为我国出境游客、留学生、出 海企业员工等客群提供跨境消费支付升级体验。该信用卡包括"双璧生辉""传世萌宗""锦绣中西""欧陆风物"四大系列，支持人民币及欧元、英镑、瑞士法郎 等10种外币直接支付。持卡者可享有免收外汇兑换手续费、欧洲消费返现及境外取现补贴等金融权益。同时，该信用卡为持卡者提供多项热门场景权益，涵 盖双语旅游管家、欧洲博物馆门票、购物礼遇、出行回馈等增值服务。 北京商报讯（记者 关子辰 牛清妍）近日，中国工商银行与欧洲旅游委员会、万事网联联合发布了工银万事达欧洲旅行联名信用卡。 ICBC European ...

北京商报讯（记者 李晗）2月3日，碧桂园披露1月未经审核经营简报。简报显示，1月碧桂园及其附属 公连同其合营公司和联营公司共实现归属公司股东权益的合同销售金额约22.1亿元，归属公司股东权益 的合同销售建筑面积约28万平方米。 ...

北京商报讯(记者王寅浩宋雨盈)2月3日，派林生物（000403）发布公告称，公司全资子公司广东双林生 物制药有限公司收到国家药品监督管理局核准签发的静注人免疫球蛋白药品补充申请《受理通知书》， 2.5g/瓶、5g/瓶和10g/瓶的静注人免疫球蛋白的境内生产药品补充申请获受理。 根据公告，静注人免疫球蛋白主要适应症包括原发性免疫球蛋白缺乏症、继发性免疫球蛋白缺陷病以及 自身免疫性疾病。目前国内拥有静注人免疫球蛋白(5g/瓶，10%，50ml)上市批件的企业包括成都蓉生药 业有限责任公司、贵州泰邦生物制品有限公司以及华润博雅生物（300294）制药集团股份有限公司。 ...